Everest Organics Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 28, 2025, 11:05 am

Competitors of Everest Organics Ltd

All Competitor Stocks of Everest Organics Ltd

Quarterly Result

Last Updated: August 19, 2025, 3:46 pm

Below is a detailed analysis of the quarterly data for Everest Organics Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 53.81 Cr.. The value appears strong and on an upward trend. It has increased from 40.93 Cr. (Mar 2025) to 53.81 Cr., marking an increase of 12.88 Cr..
• For Expenses, as of Jun 2025, the value is 49.37 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 37.49 Cr. (Mar 2025) to 49.37 Cr., marking an increase of 11.88 Cr..
• For Operating Profit, as of Jun 2025, the value is 4.44 Cr.. The value appears strong and on an upward trend. It has increased from 3.44 Cr. (Mar 2025) to 4.44 Cr., marking an increase of 1.00 Cr..
• For OPM %, as of Jun 2025, the value is 8.25%. The value appears to be declining and may need further review. It has decreased from 8.40% (Mar 2025) to 8.25%, marking a decrease of 0.15%.
• For Other Income, as of Jun 2025, the value is 0.55 Cr.. The value appears strong and on an upward trend. It has increased from 0.22 Cr. (Mar 2025) to 0.55 Cr., marking an increase of 0.33 Cr..
• For Interest, as of Jun 2025, the value is 1.31 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.15 Cr. (Mar 2025) to 1.31 Cr., marking an increase of 0.16 Cr..
• For Depreciation, as of Jun 2025, the value is 1.52 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.56 Cr. (Mar 2025) to 1.52 Cr., marking a decrease of 0.04 Cr..
• For Profit before tax, as of Jun 2025, the value is 2.16 Cr.. The value appears strong and on an upward trend. It has increased from 0.95 Cr. (Mar 2025) to 2.16 Cr., marking an increase of 1.21 Cr..
• For Tax %, as of Jun 2025, the value is 35.19%. The value appears to be increasing, which may not be favorable. It has increased from -206.32% (Mar 2025) to 35.19%, marking an increase of 241.51%.
• For Net Profit, as of Jun 2025, the value is 1.41 Cr.. The value appears to be declining and may need further review. It has decreased from 2.91 Cr. (Mar 2025) to 1.41 Cr., marking a decrease of 1.50 Cr..
• For EPS in Rs, as of Jun 2025, the value is 1.45. The value appears to be declining and may need further review. It has decreased from 3.00 (Mar 2025) to 1.45, marking a decrease of 1.55.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: November 15, 2025, 3:23 am

Growth

Last Updated: September 5, 2025, 3:26 pm

Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Everest Organics Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is -2.97. This value is below the healthy minimum of 5. It has decreased from 0.17 (Mar 24) to -2.97, marking a decrease of 3.14.
• For Diluted EPS (Rs.), as of Mar 25, the value is -2.97. This value is below the healthy minimum of 5. It has decreased from 0.17 (Mar 24) to -2.97, marking a decrease of 3.14.
• For Cash EPS (Rs.), as of Mar 25, the value is 4.81. This value is within the healthy range. It has decreased from 7.42 (Mar 24) to 4.81, marking a decrease of 2.61.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 72.03. It has increased from 57.30 (Mar 24) to 72.03, marking an increase of 14.73.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 72.03. It has increased from 57.30 (Mar 24) to 72.03, marking an increase of 14.73.
• For Dividend / Share (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 164.23. It has decreased from 246.55 (Mar 24) to 164.23, marking a decrease of 82.32.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 8.14. This value is within the healthy range. It has decreased from 14.84 (Mar 24) to 8.14, marking a decrease of 6.70.
• For PBIT / Share (Rs.), as of Mar 25, the value is 2.00. This value is within the healthy range. It has decreased from 7.60 (Mar 24) to 2.00, marking a decrease of 5.60.
• For PBT / Share (Rs.), as of Mar 25, the value is -3.34. This value is below the healthy minimum of 0. It has decreased from 0.76 (Mar 24) to -3.34, marking a decrease of 4.10.
• For Net Profit / Share (Rs.), as of Mar 25, the value is -1.33. This value is below the healthy minimum of 2. It has decreased from 0.17 (Mar 24) to -1.33, marking a decrease of 1.50.
• For PBDIT Margin (%), as of Mar 25, the value is 4.95. This value is below the healthy minimum of 10. It has decreased from 6.01 (Mar 24) to 4.95, marking a decrease of 1.06.
• For PBIT Margin (%), as of Mar 25, the value is 1.22. This value is below the healthy minimum of 10. It has decreased from 3.08 (Mar 24) to 1.22, marking a decrease of 1.86.
• For PBT Margin (%), as of Mar 25, the value is -2.03. This value is below the healthy minimum of 10. It has decreased from 0.30 (Mar 24) to -2.03, marking a decrease of 2.33.
• For Net Profit Margin (%), as of Mar 25, the value is -0.80. This value is below the healthy minimum of 5. It has decreased from 0.07 (Mar 24) to -0.80, marking a decrease of 0.87.
• For Return on Networth / Equity (%), as of Mar 25, the value is -1.84. This value is below the healthy minimum of 15. It has decreased from 0.30 (Mar 24) to -1.84, marking a decrease of 2.14.
• For Return on Capital Employeed (%), as of Mar 25, the value is 2.30. This value is below the healthy minimum of 10. It has decreased from 9.12 (Mar 24) to 2.30, marking a decrease of 6.82.
• For Return On Assets (%), as of Mar 25, the value is -0.57. This value is below the healthy minimum of 5. It has decreased from 0.06 (Mar 24) to -0.57, marking a decrease of 0.63.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.13. This value is below the healthy minimum of 0.2. It has decreased from 0.31 (Mar 24) to 0.13, marking a decrease of 0.18.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.68. This value is within the healthy range. It has decreased from 1.26 (Mar 24) to 0.68, marking a decrease of 0.58.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.70. It has decreased from 0.92 (Mar 24) to 0.70, marking a decrease of 0.22.
• For Current Ratio (X), as of Mar 25, the value is 1.06. This value is below the healthy minimum of 1.5. It has increased from 0.93 (Mar 24) to 1.06, marking an increase of 0.13.
• For Quick Ratio (X), as of Mar 25, the value is 0.73. This value is below the healthy minimum of 1. It has increased from 0.66 (Mar 24) to 0.73, marking an increase of 0.07.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.19. This value is below the healthy minimum of 4. It has decreased from 2.73 (Mar 24) to 2.19, marking a decrease of 0.54.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 1.52. This value is below the healthy minimum of 3. It has decreased from 2.17 (Mar 24) to 1.52, marking a decrease of 0.65.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.75. This value is below the healthy minimum of 3. It has decreased from 1.03 (Mar 24) to 0.75, marking a decrease of 0.28.
• For Enterprise Value (Cr.), as of Mar 25, the value is 285.94. It has increased from 148.80 (Mar 24) to 285.94, marking an increase of 137.14.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.79. This value is within the healthy range. It has increased from 0.75 (Mar 24) to 1.79, marking an increase of 1.04.
• For EV / EBITDA (X), as of Mar 25, the value is 36.15. This value exceeds the healthy maximum of 15. It has increased from 12.53 (Mar 24) to 36.15, marking an increase of 23.62.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.53. This value is within the healthy range. It has increased from 0.46 (Mar 24) to 1.53, marking an increase of 1.07.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Price / BV (X), as of Mar 25, the value is 3.50. This value exceeds the healthy maximum of 3. It has increased from 2.00 (Mar 24) to 3.50, marking an increase of 1.50.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.53. This value is within the healthy range. It has increased from 0.46 (Mar 24) to 1.53, marking an increase of 1.07.
• For EarningsYield, as of Mar 25, the value is -0.01. This value is below the healthy minimum of 5. It has decreased from 0.00 (Mar 24) to -0.01, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness